Law360, New York (November 21, 2006, 12:00 AM EST) -- Orthopedic products company ReGen Biologics Inc. said Monday that it has received a letter from the U.S. Securities and Exchange Commission’s Division of Enforcement requesting information regarding the company’s stock options-granting practices.
The investigation, disclosed in the company latest filing with the SEC, comes in the wake of the company restating past financial results.
ReGen said the SEC’s Nov. 16 letter requested “that the company preserve all documents concerning its granting of stock options to any of its executives or employees from January 2002 through the...
Orthopedic Company Comes Under SEC Scrutiny
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
